



## Drug adherence and the incidence of coronary heart disease- and stroke-specific mortality among 218,047 patients newly prescribed an antihypertensive medication: A five-year cohort study

Martin C.S. Wong<sup>a</sup>, Wilson W.S. Tam<sup>a,\*</sup>, Clement S.K. Cheung<sup>b</sup>, Harry H.X. Wang<sup>a</sup>, Ellen L.H. Tong<sup>b</sup>, Antonio C.H. Sek<sup>b</sup>, Bryan P.Y. Yan<sup>c</sup>, N.T. Cheung<sup>b</sup>, Stephen Leeder<sup>d</sup>, C.M. Yu<sup>c</sup>, Sian Griffiths<sup>a</sup>

<sup>a</sup> Jockey Club School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong

<sup>b</sup> Hospital Authority Information Technology Services – Health Informatics Section, Hong Kong

<sup>c</sup> Division of Cardiology, Department of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong

<sup>d</sup> Menzies Centre for Health Policy, University of Sydney, Australia

### ARTICLE INFO

#### Article history:

Received 20 July 2012

Received in revised form 7 October 2012

Accepted 28 October 2012

Available online 20 November 2012

#### Keywords:

Antihypertensive agents

Adherence

Cardiovascular mortality

Associated factors

### ABSTRACT

**Background:** Randomized trials have shown that optimal adherence to antihypertensive agents could protect against cardiovascular diseases, but whether adherence reduces cardiovascular deaths in community settings has not been explored so fully. This study evaluates the association between antihypertensive adherence and cardiovascular (coronary heart disease and stroke) mortality in the primary care settings.

**Methods:** From a territory-wide database in Hong Kong, we included all patients who were prescribed their first-ever antihypertensive agents in the years between 2001 and 2005 from the public healthcare sector. All patients were followed up for five years, and assigned as having poor (Proportion of Days Covered [PDC]<40%), intermediate (40–79%), and high ( $\geq 80\%$ ) adherence to antihypertensive agents. The association between antihypertensive adherence and cardiovascular mortality was evaluated by using the Cox proportional hazard models.

**Results:** From a total of 218,047 eligible patients, 3825 patients (1.75%) died of cardiovascular disease within five years after having received their first-ever antihypertensive agents. The proportions of patients having poor, intermediate, and high medication adherence were 32.9%, 12.1%, and 55.0%, respectively. Higher adherence levels at PDC 40%–79% (HR=0.46, 95% C.I. 0.41–0.52,  $p<0.001$ ) and  $\geq 80\%$  (HR=0.91, 95% C.I. 0.85–0.98,  $p=0.012$ ) were significantly less likely to be associated with mortality than the poor adherence (PDC0.040) group.

**Conclusions:** Better antihypertensive adherence was associated with lower cardiovascular mortality. This highlights the need to promote adherence through strategies which have been proved to be effective in clinical settings.

© 2012 Elsevier Ireland Ltd. All rights reserved.

### 1. Introduction

Antihypertensive pharmacotherapies are effective in reducing hypertension-induced complications, including death. In trial settings, reductions of blood pressure lowered the incidence of heart failure by 50%, stroke by 40–45%, and myocardial infarction by 20–25% [1,2]. However, it is widely recognized that a large proportion of hypertensive patients do not take antihypertensive therapies as prescribed [3], and persistence with prescriptions decreased with time especially in the first year of treatment [4–7]. Higher morbidity rates, mortality, hospitalization rates and healthcare costs have been attributed to poor medication adherence [8–11].

A recent study conducted by Mazzaglia and colleagues [12], which included more than 18,800 newly diagnosed hypertensive patients, showed that higher antihypertensive adherence was associated with a significantly lower risk of acute cardiovascular events (hazard ratio [HR] 0.62, 95% C.I. 0.40–0.96). It shows that even among those who had not experienced any such events, maintenance of optimal antihypertensive adherence confers primary prevention to a substantial extent. An accompanying editorial by Chobanian [13] argued for the importance of investigating this in greater depth because suboptimal adherence is likely to be multi-factorial. One of the major determinants includes the patients' race and ethnicity, which in turn introduces cultural and attitudinal differences [14].

Owing to this ethnic heterogeneity, more data from patients of different ethnic groups is needed to further generalize the above findings in a global context. Thus far, the impact of antihypertensive persistence on cardiovascular mortality has not been adequately

\* Corresponding author at: 4/F, School of Public Health and Primary Care, Prince of Wales Hospital, Shatin, NT, Hong Kong. Tel.: +852 2252 8810; fax: +852 2606 3500.  
E-mail address: [wilsontam@cuhk.edu.hk](mailto:wilsontam@cuhk.edu.hk) (W.W.S. Tam).

studied among patients in general non-experimental clinical settings nor more specifically in Chinese populations. Most studies on the impact of antihypertensive compliance on health outcomes have been conducted on higher-risk individuals or have used a cardiovascular (CVS) event alone as an outcome measure [15–18]. Thus, to establish the effectiveness of adherence on primary prevention of CVS mortality an even larger cohort of hypertensive patients is needed. The clinical management system (CMS) in Hong Kong hospitals allows the opportunity for just such a study.

The objectives of this study were to test the a priori hypothesis that better medication adherence leads to lower mortality from coronary heart disease and stroke in a large Chinese population, based on a recent study showing that such a relationship exists on cardiovascular events among a Caucasian population [12].

## 2. Methods

### 2.1. Data source

A detailed description of a comprehensive, territorywide database in Hong Kong has been reported previously [19–25]. Briefly, the clinical management system consists of patients' demographic profiles, prescription details, and clinical information, including diagnoses in the forms of the International Classification of Diseases (ICD-9) or the International Classification of Primary Care (ICPC-2). It is the sole portal for information used in all public clinical settings. This allows linkage of information when patients visit clinics in different districts. All physician prescriptions were checked by dispensers or pharmacists using standardized procedures, and any amendments in the prescriptions were captured in the database. A previous evaluation which assessed this database reported that socio-demographic and prescription details were 100% and 99.8% complete, respectively [19]. The sampling frame for this study included the entire population of Hong Kong, which is more than 7,000,000 as of 2012. Hong Kong has three distinct regions; these are Hong Kong Island (most urbanized); Kowloon; and the New Territories (most rural). Ethics clearance was obtained from the Clinical Ethics Research Committee of the Hospital Authority, and the Surveys and Behavioral Research Ethics Committee of the Chinese University of Hong Kong. No informed consent was required; this is because all subjects were anonymized with a unique identity number.

### 2.2. Patients

We included all patients who attended any consultations in the public sector and who were prescribed their first-ever antihypertensive medications between the calendar years 2001 to 2003 and in 2005 (the index date); the details from 2004 were excluded because the clinical services' utilization was substantially disrupted due to Severe Acute Respiratory Syndrome. We excluded patients who were prescribed any antihypertensive drugs before the index date, and treated patients who died due to conditions other than cardiovascular diseases within the observation period as being censored. We allocated each patient according to the initial prescription of antihypertensive drugs, namely,  $\alpha$ -blockers,  $\beta$ -blockers, thiazide diuretics, calcium channel blockers (CCBs) and angiotensin converting enzyme inhibitors (ACEIs). Those prescribed angiotensin receptor blockers (ARBs) and combination therapy were not included in our analysis as the number was relatively few. Concomitant comorbidities include cardiovascular risk factors and diseases which could potentially influence the choice of antihypertensive drug class, as indicated by the respective ICPC-2 or ICD-9 codes. Patients were followed up until the occurrence of cardiovascular mortality during the study or at the end of five years.

### 2.3. Outcome variables and covariates

The outcome variables included mortality due to coronary heart disease (ICD-9 I20 to I25.1) and cerebrovascular disease (ICD-9 I60–I66.9). Among all deaths in Hong Kong, the vast majority occurred in hospitals, and this allows accurate case ascertainment [26]. Deaths in hospital have been utilized in previous studies as a valid measure of patient mortality, and it is usual in Chinese populations that death occurs in hospital [26–28]. The predictor variable in this study was the interval-based PDC, defined as the number of days when medication is supplied in a specified period divided by the total number of days within the period. Interval-based PDC is an internationally accepted metric for the assessment of medication adherence in large database analysis [29–31]. A PDC  $\geq$  80% indicates that the patient is medication-adherent [29,30]. In this study we used a five-year interval for the estimation of PDC, or we used the time period between the index date and mortality if the subject died. We adopted an approach similar to Mazzaglia and colleagues [12], namely, that of classifying drug adherence into three levels: high (PDC  $\geq$  80%); intermediate (PDC = 40–70%); or low (PDC < 40%) [18,31].

The potential covariates we controlled for consist of the patients' age, gender, fee payment status (recipients vs non-recipients of public assistance; each consultation in a primary care setting including investigation and prescription fees costs approximately US\$5.77), type of clinic visits (in- and day-patient clinics, specialist outpatient

clinics [SOPCs], accident and emergency departments [AEDs], general outpatient clinic [GOPC], and other clinic types), region of residence (Hong Kong Island vs Kowloon vs the New Territories; from the most urbanized to the most rural, respectively), number of concomitant comorbidities, and the levels of systolic blood pressure and diastolic blood pressure averaged over all clinic visits. We used the same list of comorbidities by their ICD-9 and ICPC-2 coding as published elsewhere [25], categorized under "diabetes or impaired glucose tolerance" (23.0%), "cardiovascular diseases" (24.3%), "respiratory diseases" (14.6%) and "renal diseases" (11.0%).

### 2.4. Statistical analysis

Student's t-tests and Chi-square tests of heterogeneity were used to compare continuous and categorical variables, respectively. To evaluate the association between medication adherence (high vs intermediate vs low), initial antihypertensive drug class and mortality, we entered all the variables listed above into one Cox-proportional hazard model with combined coronary heart disease- and stroke-specific mortality as the outcome variable. In addition, because of the observational nature of the study, treatment indication bias might exist. Therefore, an additional analysis was conducted including adjustment of propensity scores in the Cox proportion hazard models in accordance with standard statistical methodology [32,33]. Two propensity score models were developed to estimate weightings for adherence selection, namely high vs low and intermediate vs low adherence. The absence of multicollinearity was evaluated to ensure the robustness of the regression model. The Statistical Package for Social Sciences (SPSS) version 16.0 was used for all data analyses. All  $p < 0.05$  were regarded as statistically significant.

## 3. Results

### 3.1. Patient characteristics

A total of 218,047 eligible patients were included, 3825 patients (1.75%) died of coronary heart disease or stroke within five years after being prescribed their first-ever antihypertensive agents (Table 1). Among these 3825 patients, 1371 deaths were due to coronary heart disease and 2454 deaths were due to stroke. The distribution of mortality within 5 years from different causes was shown in Fig. 1. The proportions of patients having poor, intermediate, and good medication adherence were 32.9%, 12.1%, and 55.0%, respectively. Among all the patients, the majority were females (54.9%) and aged 60 years or above (52.6%). Most (84.8%) did not receive any public assistance, and the majority attended in- or day-patient clinics (30.2%), general outpatient clinics (29.7%) or specialized outpatient clinics (29.7%). Significantly more patients lived in the most rural region (the New Territories: 48.6%) than in other more urbanized districts. Beta-blockers (45.2%) and CCBs (30.1%) were the most commonly prescribed medications, followed by ACEIs (10.5%), thiazide diuretics (8.0%), and alpha-blockers (6.2%). The majority did not suffer from any comorbidities (60.1%); with 32.5% and 7.4% having one or at least two comorbidities, respectively.

### 3.2. Profiles of cardiovascular mortality

Patients with higher medication adherence at PDC 40–79% (1.2%) had a lower incidence of cardiovascular mortality than those with low adherence levels (PDC < 40%) [1.8%], and the latter group had similar incidence than those having PDC  $\geq$  80% [1.8%]. Older patients, male subjects, those receiving public assistance and attending in- or day-patient clinics as their first visit setting had higher proportions who died from cardiovascular diseases. Residents in the most rural regions had the lowest incidence of CVS mortality (1.5% vs up to 1.7–2.1% in the more urbanized regions). Higher proportions of patients prescribed ACEIs (2.7%) and CCBs (2.7%) as their first-ever prescriptions died, followed by thiazide (1.6%), alpha-blockers (1.2%), and beta-blockers (1.0%). As the number of comorbidities increased, the cumulative incidence of cardiovascular mortality increased progressively (Table 2).

Download English Version:

<https://daneshyari.com/en/article/5974134>

Download Persian Version:

<https://daneshyari.com/article/5974134>

[Daneshyari.com](https://daneshyari.com)